Shares of Novacyt (EPA: ALNOV) today surged 8.23% higher to trade at €3.68 after the pharmaceutical company launched a diagnostic test that can differentiate between COVID-19 and the flu.
The test is part of its Winterplex test which includes two gene targets specific to COVID-19, as well as gene targets for influenza A and B, and respiratory syncytial virus (RSV).
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The tests were released just in time for the winter flu season when doctors will have to differentiate between the common cold and the coronavirus.
The new polymerase chain reaction (PCR) respiratory test can be used on any open PCR platform, including Novacyt’s portable Q32 instrument.
Graham Mullis, Novacyt’s Group CEO said: “Novacyt has established itself as a pioneer in COVID-19 diagnostics through the rapid development and success of its COVID-19 PCR test and the launch of Winterplex is another example of this innovative approach.”
Adding that:
“We believe Winterplex is one of the world’s first approved respiratory test panels that can differentiate between COVID-19 and other common respiratory diseases.”
Novacyt share price
Novacyt shares today surged 8.23% higher to trade at €3.68 having closed Friday’s session trading at €3.40.
